Opthea Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPT research report →
Range $2 – $2
Price Chart
About the company
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries.
- CEO
- Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
- IPO
- 2020
- Employees
- 33
- HQ
- South Yarra, VIC, AU
Get TickerSpark's AI analysis on OPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $25.00K-79.9%
- Gross Profit
- $25.00K+15.1%
- Op Income
- $-156,588,020
- Net Income
- $-163,795,000+25.6%
- EPS
- $-1.04+62.9%
- OCF Growth
- +1.1%
- FCF Growth
- +1.1%
- 52W High
- $6.30
- 52W Low
- $1.79
- 50D MA
- $4.37
- 200D MA
- $3.53
- Beta
- 1.67
- RSI (14)
- 39
- Avg Volume
- 32.32K
No earnings-call transcripts are available for OPT yet.
- Free Float
- 63.1%
- Shares Outstanding
- 155.27M
- Float Shares
- 98.01M
of shares held by institutions
11 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Old Mission Capital, LLC | 11.48K | ▲ 11.48K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 6, 06 | HARROLD JASON M | sell | 784 |
| Mar 6, 06 | HARROLD JASON M | sell | 785 |
| Mar 6, 06 | HARROLD JASON M | sell | 785 |
| Mar 6, 06 | HARROLD JASON M | sell | 15,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 7,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 11,250 |
| Mar 6, 06 | HARROLD JASON M | sell | 22,500 |
| Mar 6, 06 | HARROLD JASON M | sell | 125,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 25,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 45,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OPT coverage
Recent articles, reports, and earnings notes.
No research on OPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OPT report →Cavendish backs Optima Health after interim update shows 60% revenue growth and lower debt
proactiveinvestors.com · Oct 20
Optima Health revenue rises 60% after PAM Healthcare acquisition
proactiveinvestors.com · Oct 20
Cavendish lifts Optima Health target as annual profit beats forecasts
proactiveinvestors.co.uk · Aug 17
Optima Health targets further growth after transformational year
proactiveinvestors.co.uk · Aug 17
Optima Health trading 'in line' as it continues to grow UK and Ireland platform
proactiveinvestors.co.uk · Jun 16
Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again
feeds.benzinga.com · Jan 2
Novogen (NASDAQ:KZIA) & Opthea (NASDAQ:OPT) Head to Head Analysis
defenseworld.net · Dec 23
Opthea (NASDAQ:OPT) Stock Price Up 7.2% – Here’s What Happened
defenseworld.net · Nov 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.